Roche (OTCBB: RHBBY) will build a second R&D center in China, spending $100 million to create the first fully functional China clinical drug R&D center that is owned by a multinational pharmaceutical company. Until now, Roche, like many other big pharmas, has had an R&D emplacement that specializes only in specific areas of the entire R&D development path. The new center will allow Roche to bring a drug candidate to China and leave the new R&D center responsible for all the work necessary to take the drug candidate through the regulatory process. More details...
